Risk factors for the development of psoriasis

K Kamiya, M Kishimoto, J Sugai, M Komine… - International journal of …, 2019 - mdpi.com
Psoriasis is an immune-mediated genetic skin disease. The underlying pathomechanisms
involve complex interaction between the innate and adaptive immune system. T cells …

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis

E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis and comorbid diseases: epidemiology

J Takeshita, S Grewal, SM Langan, NN Mehta… - Journal of the American …, 2017 - Elsevier
Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being
recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known …

Unmet medical needs in chronic, non-communicable inflammatory skin diseases

H Ujiie, D Rosmarin, MP Schön, S Ständer… - Frontiers in …, 2022 - frontiersin.org
An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

CA Elmets, CL Leonardi, DMR Davis… - Journal of the American …, 2019 - Elsevier
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with
awareness and attention to comorbidities - ScienceDirect Skip to main contentSkip to article …

Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis

KA Papp, A Blauvelt, M Bukhalo… - … England Journal of …, 2017 - Mass Medical Soc
Background Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We
compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits …

Psoriasis and the metabolic syndrome

P Gisondi, AC Fostini, I Fossà, G Girolomoni… - Clinics in …, 2018 - Elsevier
Chronic plaque psoriasis is an immune-mediated inflammatory skin disease that is strongly
associated with the clinical features of the metabolic syndrome (MetS), including abdominal …

Psoriasis severity and the prevalence of major medical comorbidity: a population-based study

H Yeung, J Takeshita, NN Mehta, SE Kimmel… - JAMA …, 2013 - jamanetwork.com
Importance Despite the growing literature on comorbidity risks in psoriasis, there remains a
critical knowledge gap on the degree to which objectively measured psoriasis severity may …

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

JJ Wu, A Kavanaugh, MG Lebwohl… - Journal of the …, 2022 - Wiley Online Library
Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities
in addition to the characteristic skin lesions. Metabolic syndrome (MetS) is the most frequent …

[HTML][HTML] The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis

EA Dowlatshahi, M Wakkee, LR Arends… - Journal of Investigative …, 2014 - Elsevier
The reported prevalence of depression in psoriasis varies substantially. This study aims to
determine the prevalence and odds of depressive symptoms and clinical depression in …